Johnson & Johnson (J&J, NYSE: JNJ)’s consumer health spinoff Kenvue and its Chinese partner Tencent have announced an updated strategic partnership aimed at accelerating digital transformation in the healthcare sector. The collaboration will focus on the joint development of integrated online and offline health education and service solutions for patients and consumers. Financial details of the partnership were not disclosed.
The two companies initially joined forces in 2022 and plan to introduce more pediatric health brands in China in 2024, including astemizole, ibuprofen, pseudoephedrine, acetaminophen, Aveeno, and Johnson’s Baby, among others. In the public health domain, they will continue their efforts to build a smoking cessation center that integrates science popularization, patient education, online consultation, offline consultation, and e-commerce sales, aiming to provide a one-stop platform of services for smokers.
Both parties will leverage Tencent’s digital platform to explore consumer insights through big data and AIGC (Artificial Intelligence Generated Content) technology, create customized health education content, and achieve precise access to information and services for the public.- Flcube.com
